Experimental Drug Kills Breast Cancer Stem Cells In Early Trials - 12.11.09
- A new breast cancer drug, developed by Merck & Co, has passed Phase 1 trials with flying colors. The experimental drug, MK-0752, was developed to kill breast cancer stem cells that are resistant to chemotherapy and radiation.
Researchers develop stem-cell breast-growth technique - 12.11.09
- Scientists here are researching a stem-cell breast-growing technique that could help cancer victims regrow their breasts, Melbourne’s Herald Sun reports. The technique, called Neopec, could also change the cosmetic surgery industry by allowing women to grow bigger natural breasts.
Cord Blood America to Open "State of the Art" Cryogenic Lab in Las Vegas - 12.11.09
- Cord Blood America (CBAI.OB) opens its state of the art cryogenic lab in Las Vegas next month. This is big news for the cord blood storage industry as the lab has the potential to be one of the largest, if not the largest, banking lab in the US.
Stem Cells Turned Into AIDS Killers in Lab Tests - 12.11.09
- Researchers say they've shown that human stem cells can be turned into cells that can kill those infected by the virus that causes AIDS.
French biotech opens subsidiary in Mass. - 12.11.09
- Cytoo Cell Architects, a French biotechnology company focused on analysis and cell screening, yesterday became the third European life sciences company to set up shop in Massachusetts in the past two months.
Harvard Halts Construction of $1B Science Complex - 12.11.09
- The university has paused construction of its $1 billion Allston Science Complex due to the "altered financial landscape."
$11 Million to Train Stem Cell Scientists from the California Institute for Regenerative Medicine - 12.11.09
- Two critical programs funded by the California Institute for Regenerative Medicine, the state stem cell agency, got a $11 million increase today when the agency’s 29-member Governing Board voted to approve funding for two additional grants in the Training II program and five additional grants in the Bridges program.
USC Receives $3 Million for Stem Cell Training - 12.11.09
- The California Institute for Regenerative Medicine (CIRM) has awarded USC $3 million to support a training program in stem cell biology.
ImmunoCellular Therapeutics Announces Key Additions to Scientific Advisory Board - 12.11.09
- ImmunoCellular Therapeutics, Ltd. (OTC: IMUC) (IMUC), a biotechnology company that is focused on the development of novel immune-based cancer therapies, announced today that it has appointed three new members, Colonel George Peoples, M.D. Director of the Cancer Vaccine Development Program and Deputy Director of the United States Military Cancer Institute (USMCI), Dr. Constantine Ioannides, Professor of Immunology at the M.D. Anderson Cancer Center, and Dr. Cohava Gelber, Chief Scientific & Technology Officer of ATCC to its Scientific Advisory Board.
Stem Cell Therapeutics Corp. Adds Another U.S. Patent to Its Intellectual Property Portfolio - 12.11.09
- Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) announced today that it has been granted U.S. Patent No. 7,629,169 entitled "Methods for the Production of Platelet-Derived Growth Factor-Responsive Neural Precursor Cells". The claims cover methods of producing and self-renewing PDGF-responsive precursor ("PRP") cells in culture using PDGF and FGF-2.
Stem-Cell Opponents Sue State Over Ballot - 12.11.09
- Missouri's Secretary of State and Auditor manipulated ballot language to prejudice state voters against a proposed constitutional amendment by a group that opposes stem-cell research, the group claims in Federal Court.
Hard to Treat Diseases (HTDS) Comments on Recent Movement Of Its Security - 12.11.09
- Hard to Treat Diseases (HTDS) the company has been asked to comment on recent activity in its stock price. First, we would like our shareholders to be reassured and take comfort in the fact that there is no news that they do not know about.
Financial results for second fiscal quarter announced by China Cord Blood - 12.11.09
- China Cord Blood Corporation ("CCBC" or "the Company") (NYSE: CO), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced its unaudited financial results for the quarter and six months ended September 30, 2009.
Entest BioMedical to develop laser-based stem cell therapy for COPD - 12.11.09
- Entest BioMedical (La Mesa, CA), a majority owned subsidiary of Bio-Matrix Scientific Group, entered into a letter of intent with Advanced Light Devices to develop a proprietary laser system (see also "Low-level light therapy: It's all about wavelength and power" and "Cells of Parkinson's patients respond to low-level light"). It is anticipated that this investigational medical device or "regenerative photoceutical" approach will be used in conjunction with Entest's patent-pending adult stem cell therapies for treating patients with chronic obstructive pulmonary disease (COPD).
American professor placed under house arrest in stem-cell scam - 12.11.09
- Hungarian authorities have put Yuliy Baltaytis, who is suspected of illegally selling stem-cell treatments in Hungary, under house arrest, the Metropolitan Court said on its website on Thursday.
Stem cell agency triples leader Torres' salary - 12.11.09
- Directors of the state's stem cell agency voted Thursday to triple the salary of former state lawmaker and California Democratic Party Chairman Art Torres.
Stem cells from skin may chafe - 12.11.09
- When Japanese scientists found a way to tease out high-quality stem cells from adult skin, their discovery was hailed as a major breakthrough, all but rendering moot the controversy around embryonic stem cells and the related destruction of embryos.
Stem Cell Therapy Aids the Return of Lava Man - 12.11.09
- Shortly after Lava Man finished last in the 2008 Eddie Read Handicap at Del Mar, his owners decided to retire him. It seemed like the prudent thing to do at the time. Then 7, he had lost six straight races and had not won in more than a year. Age and infirmities seemed to have caught up to him.
- Celgene Corporation (NASDAQ:CELG) will participate at the 2009 Deutsche Bank Securities Biotech Boston Confab Conference on Tuesday, December 15. The company will present at 11:00 am ET that morning.
New Ethical Questions Are Being Raised in Stem Cell Research - 12.11.09
- A groundbreaking discovery two years ago that turned ordinary skin cells back into an embryonic or "pluripotent" state was hailed as the solution to the controversial ethical question that has plagued stem-cell science for the past decade. But is it?
